May 25, 2026 Log in

regulatory update

【Polaris Pharmaceuticals-KY】Voluntary Withdrawal of BLA for Pegargiminase (ADI-PEG 20) for Malignant Pleural Mesothelioma

Citation-Grade Primary-source linked Schema.org verified NQ 48 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 25, 2026 9:00 AM ・ Updated Jun 14, 2026 12:01 AM ・ 2 min read ・ Source: PR Times

Show contents

Polaris Pharmaceuticals announced on May 25, 2026, that it will voluntarily withdraw its BLA for Pegargiminase (ADI-PEG 20) for the treatment of malignant pleural mesothelioma with the US FDA, citing strategic development and lifecycle management.

PRIMARY SOURCE Original source: https://mops.twse.com.tw/material/twse-6550-2026-05-25-0df4bc37 Distributor: PR Times
Published: May 25, 2026

1. Product: Pegargiminase (ADI-PEG 20). 2. Background: The company submitted the BLA via rolling submission on Nov 16, 2023, and entered review in August 2025. 3. Reason: After evaluating development timelines, lifecycle management, and global market strategy, the company decided to withdraw to maintain flexibility for future applications. 4. Impact: This is a strategic adjustment, not a rejection by the regulator. There is no material impact on the company's financial or operational status. 5. Future: The company will continue to evaluate other indications and development paths.

FACT BOX

Source: PR Times
Category: regulatory update

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 25, 2026 9:00 AM — Distributor PR Times
Collected　May 26, 2026 8:00 AM
AI structured & analyzed　Jun 1, 2026 11:39 PM
Desk-reviewed & published　May 25, 2026 9:00 AM

FAQ

Why did the company withdraw the FDA application?

To preserve flexibility for future development based on market and lifecycle strategy.

What are the key facts in this article?

Where is the primary source?

PR Times: https://mops.twse.com.tw/material/twse-6550-2026-05-25-0df4bc37

Cite this article — HOW TO CITE

Washin AI News Desk“【Polaris Pharmaceuticals-KY】Voluntary Withdrawal of BLA for Pegargiminase (ADI-PEG 20) for Malignant Pleural Mesothelioma”AI News by Washin Village（和心村）, May 25, 2026. https://aeo.washinmura.jp/ai/%E5%8C%97%E6%A5%B5%E6%98%9F%E8%97%A5%E6%A5%AD-ky/en/news/2026-05-25-%E5%8C%97%E6%A5%B5%E6%98%9F%E8%97%A5%E6%A5%AD-ky-%E6%9C%AC%E5%85%AC%E5%8F%B8%E6%93%AC%E4%B8%BB%E5%8B%95%E6%92%A4%E5%9B%9E%E5%90%91%E7%BE%8E%E5%9C%8Bfda%E6%8F%90%E5%87%BApegargiminase-a

AI CRAWLER ACTIVITY

as of Jul 18, 2026

AI crawler visits to this article (cumulative)62 bots

Site-wide cumulative

Applebot

bot_visits_summary

4313k

last Jul 18, 2026

ClaudeBot

bot_visits_summary

2945k

last Jul 18, 2026

GPTBot

bot_visits_summary

2553k

last Jul 18, 2026

Bingbot

bot_visits_summary

2433k

last Jul 18, 2026

Meta AI

bot_visits_summary

1039k

last Jul 18, 2026

Google AI

bot_visits_summary

581k

last Jul 18, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 北極星藥業-ky Back to newsroom (159)

Copied